The CRISPR Revolution Heats Up: Intellia Therapeutics Emerges as a Clinical Frontrunner in the Race to Edit Human DNA
In the high-stakes arena of genetic medicine, a quiet revolution is unfolding, one that promises to rewrite the very code of life to cure diseases once deemed untreatable. At the epicenter of this seismic shift is CRISPR gene-editing technology, a field experiencing explosive growth and fierce competition. Among a cluster of pioneering biotech firms, Intellia…